High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels
1998

High-dose etoposide with G-CSF for mobilizing blood progenitor cells

Sample size: 63 publication Evidence: moderate

Author Information

Author(s): EJ Kanfer, D McGuigan, D Samson, Z Abboudi, G Abrahamson, JF Apperley, S Chilcott, C Craddock, J Davis, C MacDonald, D Macdonald, E Olavarria, N Philpott, GJS Rustin, MJ Seckl, M Sekhar, S Stern, ES Newlands

Primary Institution: Imperial College School of Medicine at Charing Cross and Hammersmith Hospitals

Hypothesis

Does reducing the dose of etoposide lessen toxicity without significantly affecting the effectiveness of mobilization?

Conclusion

High-dose etoposide with G-CSF is effective for mobilizing blood progenitor cells, with the lowest toxicity observed at a dose of 1.6 g m-2.

Supporting Evidence

  • 63 patients were enrolled in the study.
  • 84% of patients successfully mobilized PBPCs.
  • Median CD34+ cell collections were higher in the lower dose groups.

Takeaway

This study shows that giving a lower dose of a cancer drug can help collect important blood cells with less side effects.

Methodology

A non-randomized sequential study where patients received etoposide at three different doses followed by G-CSF, and their blood cell collections were measured.

Potential Biases

Potential bias due to the non-randomized design and the specific patient population studied.

Limitations

The study was non-randomized and included a small sample size of patients who were heavily pretreated.

Participant Demographics

63 patients with malignancy, predominantly male (75%), aged 16 to 70 years, most had received multiple prior chemotherapy regimens.

Statistical Information

P-Value

0.03

Statistical Significance

p=0.03

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication